SINGAPORE, Oct. 21 /Xinhua-PRNewswire/ -- Biosensors International
Group, Ltd., ("Biosensors" or the "Company", Bloomberg: BIG SP) is pleased
to announce that it will be participating in the Cardiovascular Research
Foundation's eighteenth annual Transcatheter Cardiovascular Therapeutics
("TCT") scientific symposium, which is being held from 22 - 27 October 2006
in Washington D.C. Biosensors will occupy booth #1450 at the Washington
Below is a schedule of major events for Biosensors at TCT (all times
are in U.S. Eastern Daylight Time):
Tuesday, Oct. 24
-- Breakfast Meeting: 7- 8 a.m.; Washington Convention Center; Room 150B.
"The New Generation of Drug-Eluting Stents - Will they Meet the
Clinical Need?" Moderated by Dr. David Holmes, Jr., Mayo Clinic,
Rochester. This breakfast meeting, sponsored by Biosensors and its
partner Xtent Inc., will offer a comprehensive look at the safety
issues of polymer on drug-eluting stents and how the two companies'
drug-eluting stent technologies fit into this safety landscape.
Speakers include: Dr. Renu Virmani, CVPath, Gaithersburg; Dr. Miodrag
Ostojic, Clinical Center of Serbia, Belgrade, Serbia; and Dr. Stephan
Windecker, Swiss Cardiovascular Center Bern, Bern, Switzerland. The
meeting will be available via webcast at Biosensors' corporate website
Thursday, Oct. 26
-- Scientific Symposia: The Drug-Eluting Stent Summit 2006: 2:00-3:50
p.m.; Washington Convention Center, Ballroom C, Level 3. Dr. David
Holmes, Jr. will present on Biosensors' BioMatrix(R) Biolimus-eluting
stent clinical programs - STEALTH, BEACON and LEADERS trials. Dr.
Thomas Ischinger will also present results and outcomes from
Biosensors' EAGLE study.
Biosensors' technology will also be presented through its partners
Terumo Corporation, Xtent Inc., and Devax Inc. A schedule of the major
events for Biosensors' partners during TCT is as follows:
Tuesday, Oct. 24
-- NOBORI 1 clinical trial results: 12.45 p.m.; Washington Convention
Center, Main Arena. Dr. Bernard Chevalier will present the nine-month
clinical and angiographic follow-up results of Terumo's NOBORI 1
clinical trial. NOBORI 1 is a prospective, randomized trial of
Biolimus A9(R) and Paclitaxel-eluting stents.
Wednesday, Oct. 25
-- Scientific Presentations:
Coronary Stent Design and New Clinical Trial Insights (Washington
Convention Center, Room 145AB)
-- 9.45 a.m. Dr. Charles Simonton will present on Xtent Inc.'s novel
modular design for customized stenting
-- 11.35 a.m. Dr. Fausto Feres will present on Devax Inc.'s Axxess
and Axxess Plus stents
-- 11.59 a.m. Dr. Akiyoshi Miyazawa et al. will present on the
intravascular ultrasound results of the Devax Inc.'s
Axxess Plus stent.
Thursday, Oct. 26
Scientific Symposia: The Drug-Eluting Stent Summit 2006 (Washington
Convention Center, Ballroom C, Level 3)
-- 2.15 p.m. Dr. Bernard Chevalier will present data on Terumo's
NOBORI Biolimus-eluting stent clinical trials
-- 2.25 p.m. Dr. Stefan Verheye will present Devax's multi-center
registry results and outcomes of its Axxess self-
expanding bifurcation Biolimus-eluting stent in the left
-- 2.35 p.m. Prof. Eberhard Grube will present on Xtent's CUSTOM
modular Biolimus-eluting stent.
Biosensors International Group
Ms Tina Lim, Executive, Corporate Communications
Tel: (65) 6213 5712
Media Relations / Investor Relations Firm
Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
About Biosensors International Group, Ltd.
Biosensors develops, manufactures and markets innovative medical
devices used in interventional cardiology and critical care procedures.
Biosensors is well-positioned to emerge as a leader in drug-eluting stents,
an evolving therapy that is rapidly gaining market share from traditional
therapies such as bare-metal stenting and open-heart surgery. Biosensors
has internally developed technology to address each component of a
drug-eluting stent system, including a stent, a stent delivery catheter, a
biodegradable polymer and a proprietary anti-restenotic drug. It is
pursuing two separate drug-eluting stent programs, BioMatrix(R) and
Axxion(TM), and has licensed aspects of its drug-eluting stent technology
to four companies.
Forward Looking Statements
Certain statements herein include forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward- looking statements generally can be identified by the use of
forward-looking terminology, such as "may," "will," "expect," "intend,"
"estimate," "anticipate," "believe," "project" or "continue" or the
negative thereof or other similar words. All forward-looking statements
involve risks and uncertainties, including, but not limited to, customer
acceptance and market share gains, competition from companies that have
greater financial resources; introduction of new products into the
marketplace by competitors; successful product development; dependence on
significant customers; the ability to recruit and retain quality employees
as Biosensors grows; and economic and political conditions globally. Actual
results may differ materially from those discussed in, or implied by, the
forward-looking statements. The forward- looking statements speak only as
of the date of this release and Biosensors assumes no duty to update them
to reflect new, changing or unanticipated events or circumstances.
SOURCE Biosensors International Group, Ltd.